Dr. Michael Rybak Joins Ceragenix's Scientific Advisory Board.DENVER -- Ceragenix Pharmaceuticals, Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :CGXP), a biopharmaceutical company focused on infectious disease and dermatology, today announced Michael J. Rybak, PharmD, MPH, FCCP, FIDSA FIDSA Fellow of the Infectious Diseases Society of America , has joined its scientific advisory board. Dr. Rybak is the associate dean for research and professor of pharmacy at the Eugene Applebaum College of Pharmacy A college of pharmacy generally refers to a tertiary educational institution (or part of such an institution) which is involved in the education of future pharmacists and pharmaconomists. and Health Sciences (EACPHS), and an adjunct professor of medicine in the Division of Infectious Diseases at the School of Medicine at Wayne State University Wayne State University, at Detroit, Mich.; state supported; coeducational; established 1956 as a successor to Wayne Univ. (formed 1934 by a merger of five city colleges). in Detroit, Michigan. Dr. Rybak also serves as the director of the Anti-Infective Research Laboratory at the EACPHS, and is affiliated with Detroit Receiving Hospital and University Health Center. He received his B.S. in Pharmacy from Northeastern University, PharmD from the College of Pharmacy and Health Sciences, and MPH from the School of Medicine at Wayne State University. Important to Ceragenix's developing line of anti-infectives, Dr. Rybak's primary research focus is antimicrobial pharmacokinetics and pharmacodynamics and their relationship to bacterial resistance. He has published more than 200 manuscripts, book chapters, and review articles in scientific journals on topics that included antimicrobial PK/PD and resistance to antimicrobial agents, the importance of bactericidal bactericidal /bac·te·ri·ci·dal/ (bak-ter?i-si´d'l) destructive to bacteria. Bactericidal An agent that destroys bacteria (e.g. drugs, and the assessment of patient outcome as it relates to antimicrobial resistance issues. He is a member of several professional societies, including the American College of Clinical Pharmacy, the American Society of Health-System Pharmacists The American Society of Health-System Pharmacists (ASHP) is a professional organization representing the interests of pharmacists who practice in hospitals, health maintenance organizations, long-term care facilities, home care, and other components of health care systems. , the Society of Infectious Diseases Pharmacists, the American Society for Microbiology The American Society for Microbiology (ASM) is a scientific organization, based in the United States although with over 43,000 members throughout the world. It is the largest single life science professional organization and its members include those whose interests encompass basic , and the Infectious Diseases Society of America The Infectious Diseases Society of America (IDSA) is a medical association representing physicians, scientists and other health care professionals who specialize in infectious diseases. . He is also a fellow of both the American College of Pharmacy and the Infectious Diseases Society of America. Dr. Rybak serves as the scientific field editor for the infectious diseases section of Pharmacotherapy, as well as an editorial reviewer for a number of other scientific publications. "We are fortunate and honored to have Dr. Rybak join our scientific advisory board," said Steven Porter, chairman and chief executive officer of Ceragenix. "We will benefit from his expert advice and years of experience in the field of infectious diseases and anti-infective research." Rybak joins a number of other esteemed scholars and researchers on the Ceragenix scientific advisory board, which includes Dr. Peter Elias of UCSF, Dr. Henry F. Chambers of San Francisco General Hospital San Francisco General Hospital is the main public hospital in San Francisco, California, and the only Level I Trauma Center serving San Francisco and San Mateo. The hospital budget is for only 302 beds at SFGH. , Dr. Tomas Ganz of UCLA, Dr. Richard Gallo of UCSD, Dr. Donald Y. Leung of the National Jewish Medical Center, and Professor Sean Gorman of Queens University, Belfast, UK. About Ceragenix Ceragenix Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, develops and commercializes novel anti-infective drugs based on its proprietary class of compounds, Ceragenins[TM] (or CSAs). Active against a broad range of gram positive and negative bacteria, these agents are being developed as anti-infective medical device coatings (Ceracides[TM]) and as therapeutics for antibiotic-resistant organisms. Ceragenix also owns exclusive rights to Barrier Repair Technology for the treatment of dermatological disorders including atopic dermatitis, neonatal skin disorders and others. Ceragenix's patented Barrier Repair Technology, invented by Dr. Peter Elias and licensed from the University of California The University of California has a combined student body of more than 191,000 students, over 1,340,000 living alumni, and a combined systemwide and campus endowment of just over $7.3 billion (8th largest in the United States). , is the platform for the development of two prescription topical creams--EpiCeram[TM] and NeoCeram[TM]. For additional information on Ceragenix, please visit www.ceragenix.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion